Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | EURO-SKI: 3-year follow-up data of TKI cessation in CML

Given the success of tyrosine kinase inhibitors (TKIs) to treat chronic myeloid leukemia (CML), European LeukemiaNet recommendations suggest that treatment cessation is feasible in patients with a stable deep molecular response (DMR). The EURO-SKI trial (NCT01596114) was established to investigate molecular recurrence-free survival in patients with CML after stopping TKI treatment. Patients with confirmed DMR for ≥ 1 year and at least 3 years of TKI treatment were eligible. Previously reported data from the interim analysis of 200 patients in EURO-SKI showed that 62% were in major molecular response (MMR: less than 0.1% BCR-ABL1) at 6 months. Francois-Xavier Mahon, MD, PhD, University of Bordeaux, Bordeaux, France, discusses the final analysis of EURO-SKI, after a median follow-up of 3 years. At 36 months, 46% of the 678 analyzable participants were in MMR and molecular recurrence- and treatment-free survival (MRecTFS) was 46%. TKI treatment duration and DMR duration prior to cessation were the most significant predictors of MMR loss at 6 months. TKI duration was also relevant to late recurrence. Further investigation into the mechanisms of late recurrence is needed. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.